Bioluminiscence

Bioluminescence Ventures was conceptualized to finance breakthrough platforms and support mission-driven leaders to develop first-in-class or best-in-class therapies for patients with major unmet medical needs.

Bioluminescence is a leading US biotechnology venture capital firm investing in the future of medicine. They are inspired by the accelerating pace of biomedical innovation and its recent impact on humanity. They are mission-driven – investing their time, energy, and capital into translating transformative science into next-generation medicines that will impact patients. They believe that, as long as we continue to succeed in this endeavor, then strong financial returns will follow. The firm focuses investments on four areas: Breakthrough Biology, Drug Discovery Platforms, Genetic Medicines Platforms, and Computational Biology Platforms.

They have launched a $350 million first fund aimed at faster development of experimental drugs.

Portfolio: Surge, Ensoma, Recode, Nido Bio.